Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients
Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients
复制标题
DOI：
10.1111/bjh.16659
复制
发表时间：
2020-04-20
影响因子：
6.5
通讯作者：
Gao, Cailiang
中科院分区：
文献类型：
--
作者：
Wan, Suxin;Yi, Qingjie;Gao, Cailiang
我们探讨了新冠肺炎患者淋巴细胞亚群、细胞因子、肺部炎症指数(PII)与疾病演变的关系。将123例新冠肺炎患者分为轻度组和重度组。在入院第一天检测淋巴细胞亚群和细胞因子，肺CT结果用PII进行量化。对两组进行差异分析和相关分析。共有102名轻症患者和21名重症患者被纳入分析。分化集落4(+)T、CD8(+)T、白介素6(IL-6)、白介素10(IL-10)、PII在两组间差异有统计学意义。轻度组CD4(+)T与CD8(+)T、IL-6、IL-10呈显著正相关(r(2)=0中心点694，r(2)=0中心点633；P<；0中心点01)。经“五位一体”治疗后，除四人死亡外，其余病人均已出院。轻度组和IL-6在正常值范围内的患者存活率较高。CD_4(+)T、CD_8(+)T、IL-6、IL-10和PII可作为疾病进展的指标，PII可作为新冠肺炎疾病进展的独立指标。
We explored the relationships between lymphocyte subsets, cytokines, pulmonary inflammation index (PII) and disease evolution in patients with (corona virus disease 2019) COVID-19. A total of 123 patients with COVID-19 were divided into mild and severe groups. Lymphocyte subsets and cytokines were detected on the first day of hospital admission and lung computed tomography results were quantified by PII. Difference analysis and correlation analysis were performed on the two groups. A total of 102 mild and 21 severe patients were included in the analysis. There were significant differences in cluster of differentiation 4 (CD4(+ )T), cluster of differentiation 8 (CD8(+ )T), interleukin 6 (IL-6), interleukin 10 (IL-10) and PII between the two groups. There were significant positive correlations between CD4(+ )T and CD8(+ )T, IL-6 and IL-10 in the mild group (r(2) = 0 center dot 694, r( 2) = 0 center dot 633, respectively; P < 0 center dot 01). After 'five-in-one' treatment, all patients were discharged with the exception of the four who died. Higher survival rates occurred in the mild group and in those with IL-6 within normal values. CD4(+ )T, CD8(+ )T, IL-6, IL-10 and PII can be used as indicators of disease evolution, and the PII can be used as an independent indicator for disease progression of COVID-19.